Originated from Tokyo University, drug discovery firm PeptiDream recently competes pre-clinical study for its anti-flu peptide PD-001, after signing 17 deals with large drug makers in 11 years. The company's CEO Patrick Reid outlines to Scrip prospects of peptide-drug conjugates (PDCs) and discovery strategy.
Kanagawa, Japan-based biotech startup PeptiDream Inc. has signed licensing deals with many multinational drug makers, 17 in total in 11 years, courting Roche's Genentech, Janssen Pharmaceuticals Inc. and Shionogi & Co. Ltd., among others.
The key to this track record is its proprietary Peptide Discovery Platform System (PDPS) platform, in particular, peptide-drug conjugates (PDCs),...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.
BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.
With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
